CJC-1295 Nasal Spray – vial only – (Mod GRF 1-29) – 2MG per vial

Clinical Test Expectation CJC-1295 Nasal Spray – Human Subjects : Increased growth hormone secretion and IGF-1 Levels with no increase in prolactin. Increased body weight and length through increased protein synthesis. Increased muscle growth and bone density. Improved immune function, cognition and memory. Increased collagen production, fat loss and cellular repair and regeneration. Strength – 2MG per vial

Dosing Details Inject 1 ml water into the vial of CJC-1295 Nasal Spray from the vial of water. 1 ml is a full syringe. Draw out all the contents of the vial once mixed and clear in colour and inject into the nasal bottle. Then inject the balance of all the water in the 2 water vials 5ml each / 1 vial 10ml into the nasal bottle. So in total there will be 10ml water in the nasal bottle and the contents of the vial. Spray 2 times per nostril at night before bed.

Although this item is a different version of the injectable peptide, the action and mechanisms of action are the same. For more information on the action and mechanisms of action for this product please click here : CJC-1295 (Modified Growth Hormone-Releasing Factor 1-29) – 2MG per vial

Do I pick the nasal or the injectable ? Which is better ?? Biologically they are the same in terms of result just that they differ in terms of method of absorption. The selection of one or the other is normally based on preference. Also some people do report one or the other to have worked better for them. We are not sure what causes this variance as they are both the same in terms of action and strength. It is only the absorption method that varies by design respectively

Clinical Test Expectation PEG-MGF - Human Subjects : Promotes muscle repair. Speeds up bone repair. Stimulates muscle growth. Prevents heart disease. Protects against stroke. Promotes cognitive health Strength - 2MG per vial

Introduction Pegylated Mechano Growth Factor (PEG MGF) is a derived form of the IGF-1 (insulin-like growth factor-1), which stimulates myoblasts division and allows for muscle fibers to fuse and mature. This is a process necessary for growth of adult muscle.

PEG-MGF modulates muscle inflammation and enhances the regeneration process by improving the recruitment of the white blood cells called macrophages and neutrophils to the site of injury. This in turn promotes muscle growth and repair. PEG-MGF also promotes neurogenesis (formation of new nerve cells or neurons) by increasing the number of neural progenitor cells (cells that transform to create specialized cell types).

Benefits of PEG-MGF

• Promotes muscle repair
• Speeds up bone repair
• Stimulates muscle growth
• Prevents heart disease
• Protects against stroke
• Promotes cognitive health

Pegylation is a process of attaching polyethylene glycol to another chemical compound. It is often done to reduce the body’s natural immune reaction to an agent or, as in the case of PEG-MGF, to increase the half-life of the compound in the blood by reducing clearance in the kidneys. Pegylation is common, safe, and has a number of advantages. PEG-MGF was developed because MGF has a very short half-life in blood. Though it persists for longer periods of time in muscle tissue, MGF administered exogenously has a short half-life because it passes through the blood stream first unless it is injected directly into muscle tissue. PEG-MGF helps to offset this particular disadvantage.

Dosing Details You inject 2ml water into the vial of PEG MGF from the water vial. 1 full syringe is 1ml. You then wait for the vial powder content to dissolve ON ITS OWN. DO NOT SHAKE THE VIAL TO MIX POWDER. Once dissolved and clear in color you draw out 20 - 40 (2 - 4 units) on the syringe and inject 3 times a week evenly spacing injections.

How long will a vial last ? A vial should last 10-14 days.

Clinical Test Expectation BPC 157 Nasal Spray – Human Subjects : Super fast joint, tendon, ligament healing. Heal wounds in internal organs, muscles, ligaments, tendons, skin, internal lacerations from surgery Strength – 5MG per vial

Dosing Details Inject 1 ml water into the vial of BPC 157 Nasal Spray Acetate from the vial of water. 1 ml is a full syringe. Draw out all the contents of the vial once mixed and clear in colour and inject into the nasal bottle. Then inject the balance of all the water in the 2 water vials 5ml each / 1 vial 10ml into the nasal bottle. So in total there will be 10ml water in the nasal bottle and the contents of the vial. Spray 2 times per nostril at night before bed.

Although this item is a different version of the injectable peptide, the action and mechanisms of action are the same. For more information on the action and mechanisms of action for this product please click here : BPC 157 (Pentadecapeptide (PL 14736)) – 5MG per vial

Do I pick the nasal or the injectable ? Which is better ?? Biologically they are the same in terms of result just that they differ in terms of method of absorption. The selection of one or the other is normally based on preference. Also some people do report one or the other to have worked better for them. We are not sure what causes this variance as they are both the same in terms of action and strength. It is only the absorption method that varies by design respectively

Clinical Test Expectation Hexarelin Nasal Spray – Human Subjects : Lean muscle growth. Rapid fat loss. Increased tendon and ligament strength. Enhanced flexibility. Better recovery. Cardiovascular aid Strength – 2MG per vial

Dosing Details Inject 1 ml water into the vial of Hexarelin Nasal Spray from the vial of water. 1 ml is a full syringe. Draw out all the contents of the vial once mixed and clear in colour and inject into the nasal bottle. Then inject the balance of all the water in the 2 water vials 5ml each / 1 vial 10ml into the nasal bottle. So in total there will be 10ml water in the nasal bottle and the contents of the vial. Spray 2 times per nostril at night

Although this item is a different version of the injectable peptide, the action and mechanisms of action are the same. For more information on the action and mechanisms of action for this product please click here : Hexarelin (HEX) – 2MG per vial

Do I pick the nasal or the injectable ? Which is better ?? Biologically they are the same in terms of result just that they differ in terms of method of absorption. The selection of one or the other is normally based on preference. Also some people do report one or the other to have worked better for them. We are not sure what causes this variance as they are both the same in terms of action and strength. It is only the absorption method that varies by design respectively

Clinical Test Expectation Tesamorelin Nasal Spray – Human Subjects : Reduce Belly Fat. Also used to assist with HIV induced belly fat. Strength – 2MG per vial

Dosing Details Inject 1 ml water into the vial of Tesamorelin Nasal Spray from the vial of water. 1 ml is a full syringe. Draw out all the contents of the vial once mixed and clear in colour and inject into the nasal bottle. Then inject the balance of all the water in the 2 water vials 5ml each / 1 vial 10ml into the nasal bottle. So in total there will be 10ml water in the nasal bottle and the contents of the vial. Spray 2 times per nostril at night before bed.

Although this item is a different version of the injectable peptide, the action and mechanisms of action are the same. For more information on the action and mechanisms of action for this product please click here : Tesamorelin – 2MG per vial

Do I pick the nasal or the injectable ? Which is better ?? Biologically they are the same in terms of result just that they differ in terms of method of absorption. The selection of one or the other is normally based on preference. Also some people do report one or the other to have worked better for them. We are not sure what causes this variance as they are both the same in terms of action and strength. It is only the absorption method that varies by design respectively

Clinical Test Expectation VIP Nasal Spray – Human Subjects : Proven Covid-19 blocker. Covid19 critical recovery. Gut repair. Increases glycogenolysis. Contractility in the heart. Lowers arterial blood pressure. Relaxes the smooth muscle of trachea, stomach and gallbladder. Regulates prolactin secretion. Full balancing of circadian rhythm. Can assist with osteoarthritis Strength – 1MG per vial

Introduction ( VIP Nasal Spray ) Vasoactive intestinal peptide, also known as vasoactive intestinal polypeptide or VIP, is a peptide hormone that is vasoactive in the intestine. VIP is a peptide of 28 amino acidresidues that belongs to a glucagon/secretin superfamily, the ligand of class II G protein–coupled receptors. VIP is produced in many tissues of vertebrates including the gut, pancreas, and suprachiasmatic nuclei of the hypothalamus in the brain. VIP stimulates contractility in the heart, causes vasodilation, increases glycogenolysis, lowers arterial blood pressure and relaxes the smooth muscle of trachea, stomach and gallbladder. In humans, the vasoactive intestinal peptide is encoded by the VIP gene.

The vasoactive intestinal peptide (VIP) also known as the vasoactive intestinal polypeptide is a neuropeptide that belongs to a glucagon/secretin superfamily, the ligand of class II G protein-coupled receptors. It was initially reported to be expressed in lung and small intestine tissue; however, currently it is also described in neurons of central nervous system (CNS). Beside the neuronal source, VIP is also expressed and released from endocrine organs (such as heart, thyroid, kidney and gastrointestinal tracts) and immune organs (such as spleen, thymus, bone marrow and lymph nodes). VIP plays essential roles in a broad spectrum of biological functions. It stimulates contractility in the heart, causes vasodilation, promotes neuroendocrine-immune communication, increases glycogenolysis and lowers arterial blood pressure. VIP displays potent anti-inflammatory and immune-modulatory activity and modulation of VIP level has considered being a potential candidate for treatment of inflammatory and autoimmune diseases including acute pancreatitis, septic shock, inflammatory bowel disease, lipopolysaccharide (LPS)-induced acute inflammation and arthritis.

Osteoarthritis (OA) is a chronic and degenerative disease that results from the breakdown of articular cartilage components (particularly type II collagen and cartilage specific proteoglycans) and extensive remodeling of subchondral bone leading to synovitis as well as osteophyte formation. OA is the most common form of arthritis with disease of near the ends of the fingers, lower back, knees and hips which may affect weight bearing, mobility and normal daily activities. It is one of the most common causes of disability and most common in both sexes as people become older. Among adults in the age of over 60 years, the prevalence of OA is approximately 10 % in men and 13 % in women. The exact cause of OA is unclear. The etiology of OA is complex and multi-factorial including age, sex, and body weight, genetic, biological and biomechanical components. OA is believed to be caused by previous joint injury, abnormal limb development or mechanical stress on the joint. The most common clinical symptoms of OA are joint pain, swelling, decreased range of motion and stiffness. The joint pain is mainly due to the inflammation effects and the sensitization of neurobiological processes and further stimulation cascade of inflammation responses. During inflammation, mechanical stimuli sensitize joint nerves the actions of certain neuropeptides, eicosanoids, proteinase-activated receptors and ion channel ligands. Usually the inflammatory neuropeptides substance P, calcitonin gene-related peptide, as well as VIP, have all been reported to be immunolocalized in joint tissues and their levels are increased in arthritis.

Treatment of OA includes exercise, lifestyle modification and pain medications. The treatment of OA is still restricted to analgesics which have some undesirable and hazardous side effects. If the conventional management is ineffective and pain interferes with normal life, joint replacement surgery may be recommended. Evidence supports that joint replacement is both clinically effective and cost-effective; however, the functional and clinical outcomes can be poor. Therefore, alternative therapeutics is urgently needed that could improve the survival rate and quality of life of OA patients. A better understanding of the pathological mechanisms by which it promotes initiation and maintenance of joint pain in OA may help to identify the more effective targets to counteract the debilitating symptoms of OA.

Evidence suggests that VIP is shown to prevent chronic cartilage damage and joint remodeling. It shows the therapeutic function in rheumatoid arthritis (RA); however, the protective function of VIP in the progression of OA is not fully explained. In this review, we have focused on the association of VIP in the development and progression of OA and the potential effects of VIP as a therapeutic agent for the treatment of OA.

Vasoactive intestinal peptide (VIP) is one of the most abundant molecules found in the respiratory tract. Due to its anti-inflammatory and bronchodilatatory properties, it has been proposed as a novel treatment for chronic obstructive pulmonary disease (COPD).

Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy. Vasoactive intestinal peptide (VIP) is shown in nonclinical studies to upregulate surfactant production, inhibit cytokine synthesis, prevent cytopathy, and block replication of the severe acute respiratory syndrome coronavirus 2 virus in pulmonary cells. The study aims to determine whether Aviptadil (synthetic VIP) can improve survival and recovery in patients with COVID-19 respiratory failure compared with placebo and demonstrate biological effects in such patients.

Dosing Details Inject 1 ml water into the vial of VIP Nasal Spray from the vial of water. 1 ml is a full syringe. Draw out all the contents of the vial once mixed and clear in colour and inject into the nasal bottle. Then inject the balance of all the water in the 2 water vials 5ml each / 1 vial 10ml into the nasal bottle. So in total there will be 10ml water in the nasal bottle and the contents of the vial. Spray 2 times per nostril at night before bed.